Popular Pre-Market Trades in US Stocks

Jianzhi Edu Tech, down 7.85% in pre-market, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Entegris, up 7.19% in pre-market, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Top Gainers in Pre-Market US Stocks

NextCure up 336.22% in pre-market. Based on recent news,

1. On July 14, NextCure announced it would merge with Avere Therapeutics and will operate under the name Avere Therapeutics. This news significantly boosted NextCure's stock price. After the merger, Avere shareholders will hold approximately 98.8% of the merged company, while NextCure shareholders will hold only about 1.2%.

2. On July 14, NextCure announced it secured $320 million in private financing to develop AVR-001, an experimental weekly pill for inflammatory diseases. This financing news further boosted market confidence.

3. On July 14, Hansoh Pharmaceutical announced it signed an exclusive licensing agreement with Avere, granting Avere exclusive rights to develop, manufacture, and commercialize AVR-001 globally (excluding mainland China, Hong Kong, Macau, and Taiwan). This news also positively impacted NextCure's stock price. The biotechnology sector has been active recently, with significant capital inflow.

Shuttle Pharmaceuticals up 51.95% in pre-market. Based on recent key news:

1. On July 13, HRT Financial LP increased its direct holdings in Shuttle Pharmaceuticals, purchasing 8,997 shares at prices between $3.11 and $3.38. This move shows confidence in the company's stock, driving the price up. Source: EDGAR system announcement.

2. On July 13, HRT Financial reported a 10% stake in Shuttle Pharmaceuticals in Form 3, showing it held 60,540 shares of common stock as of July 9. This holding information further enhanced market interest in the company's stock. Source: EDGAR system announcement. Market interest in the biopharmaceutical sector is increasing.

Vision Marine Tech up 42.55% in pre-market. Based on recent key news:

1. On July 13, Vision Marine Technologies released an announcement on the EDGAR system, disclosing recent financial and operational information. This announcement may have enhanced investor confidence in the company's future development, driving the stock price up

2. On July 9th, HRT Financial sold its 34,746 shares of common stock in Vision Marine Technologies at a price of $1.25 per share. Nevertheless, demand for the stock remains strong, leading to a significant pre-market increase in its price.

3. Recently, Vision Marine Technologies has faced risks such as supply chain disruptions, tariffs, and trade policies, but the company's progress in technology development and commercialization may have boosted market confidence. Supply chain risks and technological advancements influence market sentiment